Results 161 to 170 of about 7,735 (207)

Integrated analysis of CD30 detection methodologies and synergistic drug combinations for optimizing brentuximab vedotin therapy in lymphoma. [PDF]

Clin Exp Med
Ye M, Wang T, Song Z, Liu X, Liu P, Zhang L, Tang G, He M, Liu N, Yang J.   +9 more
europepmc   +1 more source

[Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board]. [PDF]

Pathologie (Heidelb)
Dopfer EP, Fahrner M, Thiery J, Riemer Cysar S, Heyer J, Bronsert P, Becker H, Kuehn JC, Lowinus T, Gräßel L, Rawluk J, Boerries M, Barsch M, Quante M, Peters C, Duyster J, Schultheis A, Werner M, Miething CC, Schilling O, Timme-Bronsert S.   +20 more
europepmc   +1 more source

Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary. [PDF]

Future Oncol
Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Boni J.   +11 more
europepmc   +1 more source

246 New platforms of immunoconjugates

European Journal of Cancer Supplements, 2010
openaire   +1 more source

Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration. [PDF]

Blood Adv
Gao L, Kallam A, Shouse G, Baird JH, Pak S, Qin Y, Song JY, Marcucci G, Ghoda LY, Guillen C, Hyung SJ, Saad OM, Davis H, Dere R, Batlevi CL, Meinert J, Budde LE, Danilov AV, Herrera AF, Kwak LW, Forman SJ, Godfrey JK.   +21 more
europepmc   +1 more source

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. [PDF]

Adv Ther
Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F.   +16 more
europepmc   +1 more source

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study. [PDF]

Future Oncol
Smit EF.
europepmc   +1 more source

Efficient Preparation of Homogenous Antibody Conjugates via Glycosite-Specific Transglycosylation Enabled by Readily Available Glycosyl Donors. [PDF]

Angew Chem Int Ed Engl
Cai D, Zhao Y, Lu G, Li C, Lao Y, Mudududdla R, Zhang J, Jia P, Huang P, Wu W, Nguyen TT, Huang X, Li L, Tang W.   +13 more
europepmc   +1 more source

¹⁶¹Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas. [PDF]

J Nucl Med
Rioja-Blanco E, Banz Y, Schlapbach C, Novak U, Chiorazzo T, Bertschi NL, Bernhardt P, Grundler PV, van der Meulen NP, Grzmil M, Schibli R, Behe M.   +11 more
europepmc   +1 more source